New hope for rare artery disease? small trial tests upadacitinib

NCT ID NCT07500467

Completed Disease control Sponsor: Liu Tian Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study tested the drug upadacitinib in 12 people with refractory Takayasu arteritis, a rare autoimmune disease that inflames the body's largest artery. The goal was to see if the drug could help patients who haven't responded to standard treatments achieve remission within 24 weeks. The trial focused on safety and how many patients experienced partial or complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat Takayasu arteritis.
What could go wrong: This is a very small, early-phase study with only 12 participants, so results may not apply widely. The drug also carries risks like infection and side effects common to JAK inhibitors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Takayasu arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TAKAYASU ARTERITIS

Contacts and locations

Locations

Department of Rheumatology and Immunology, Peking University People's Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.